SYNDAX PHARMACEUTICALS INC
NASDAQ: SNDX (Syndax Pharmaceuticals, Inc.)
Last update: yesterday, 12:47AM9.85
-0.96 (-8.88%)
| Previous Close | 10.81 |
| Open | 10.98 |
| Volume | 3,830,095 |
| Avg. Volume (3M) | 2,294,496 |
| Market Cap | 847,566,912 |
| Price / Sales | 20.91 |
| Price / Book | 4.26 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -416.67% |
| Diluted EPS (TTM) | -3.85 |
| Total Debt/Equity (MRQ) | 160.71% |
| Current Ratio (MRQ) | 5.80 |
| Operating Cash Flow (TTM) | -286.52 M |
| Levered Free Cash Flow (TTM) | -169.65 M |
| Return on Assets (TTM) | -36.29% |
| Return on Equity (TTM) | -93.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Syndax Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.30% |
| % Held by Institutions | 120.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stempoint Capital Lp | 31 Dec 2024 | 2,872,601 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (HC Wainwright & Co., 417.77%) | Buy |
| Median | 41.00 (316.24%) | |
| Low | 17.00 (Scotiabank, 72.59%) | Hold |
| Average | 36.60 (271.57%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 12.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 06 May 2025 | 32.00 (224.87%) | Buy | 10.64 |
| Scotiabank | 06 May 2025 | 17.00 (72.59%) | Hold | 10.64 |
| JP Morgan | 20 Mar 2025 | 41.00 (316.24%) | Buy | 14.10 |
| 04 Mar 2025 | 39.00 (295.94%) | Buy | 14.38 | |
| Citigroup | 04 Mar 2025 | 42.00 (326.40%) | Buy | 14.38 |
| HC Wainwright & Co. | 04 Mar 2025 | 51.00 (417.77%) | Buy | 14.38 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |